Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study - Wikidata - wikimedia - TriplyDB

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

http://www.wikidata.org/entity/Q34480536

about

Temozolomide for high grade glioma 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2 Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Involvement of long noncoding RNAs in diseases affecting the central nervous system Therapeutic cancer vaccines: past, present, and future Extracellular matrix as a contextual determinant of transforming growth factor-β signaling in epithelial-mesenchymal transition and in cancer Tumor stroma as targets for cancer therapy Complexities of TGF-β targeted cancer therapy.TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?TGF-β signaling and its targeting for glioma treatment Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme Convection-Enhanced Delivery of Carboplatin PLGA Nanoparticles for the Treatment of Glioblastoma Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Neurosurgical oncology: advances in operative technologies and adjuncts.The roles of TGFβ in the tumour microenvironment.Strategies to use immune modulators in therapeutic vaccines against cancer Novel clinical therapeutics targeting the epithelial to mesenchymal transition Cancer association study of aminoacyl-tRNA synthetase signaling network in glioblastoma Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer.DiME: a scalable disease module identification algorithm with application to glioma progression Targeting tumor cell motility to prevent metastasis.First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.Transforming growth factor-β pathway activity in glioblastoma.Current trends in targeted therapies for glioblastoma multiforme Therapeutic cancer vaccines: current status and moving forward.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.TGF-β1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)Immunosuppressive mechanisms in glioblastoma.Exploring the key genes and signaling transduction pathways related to the survival time of glioblastoma multiforme patients by a novel survival analysis model.TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.Targeting the TGFβ signalling pathway in disease.Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.Comparison of pulsed versus continuous convective flow for central nervous system tissue perfusion: laboratory investigation.Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic.

P2860

Q24197645-54884708-D5B2-465D-9827-D4EAB3BD8CB5 Q24318575-DBFC8836-BDFE-419D-96C8-07E2ECBD1919 Q26750579-E6CF4BE0-FF23-4C8E-A846-BA50C8BCD06F Q26771386-139CA281-0CE0-4069-81AD-C3EA40AEF73F Q26797238-8D63CF17-CB34-4D0F-9C74-037956BC3048 Q26798402-3A4B7C52-2E49-4563-996E-92B9F361BD2C Q26852160-14A07832-C1D4-4342-A41A-5668FE72510D Q26863283-365DB0BA-4310-4332-A367-FA1F789AE220 Q27005909-37A088B8-C7D6-42E6-BA4A-D8B0F5F7C2CE Q27015980-8E09F090-1889-40F1-AE6B-71A3EAAAE6D0 Q27693607-6B5A821A-DD87-4FE5-B3D8-062FADBCC2A6 Q28076815-AF32A8D8-685F-40EF-83FA-A2A50B6F29B2 Q28078539-E0614FDF-A51E-4094-B420-68F21D61C0DC Q28082042-EA91840D-1660-440D-92F5-FCC20BE145D3 Q28087485-C11FA49A-2849-4033-AFD2-463C0DDC238A Q28546653-A59F6DF4-3B6D-42F7-9616-9F33699495B5 Q30366921-63C59DBE-AD5D-4BED-A2D0-B881D8B7FE87 Q30833619-22FD2B06-7E8A-4AA5-A57C-31541FB49FE6 Q33630845-746F0E19-2105-4888-9470-E4754532CBE8 Q34275601-DD506B43-7EF4-4DB0-B080-1AB17B3EEDD3 Q34345818-E76AE75B-45B7-45A9-B881-FBCD511A426D Q34404633-810B2455-F2B6-48E8-85F9-639D2D9928D7 Q34644776-4168C63B-16E5-46D7-97BC-FBB4A6FC6998 Q35093523-6D7EF2C1-70B2-4B14-A970-1D9187029C1A Q35095152-258A3BA9-FA87-4B9B-8296-9D01674F9BB0 Q35111925-EF549AE5-B3D2-49D5-BCD6-1BFFF9D4D8EF Q35222167-68C06E90-2837-47D0-B04F-A5CDE001FCB8 Q35289038-C35495C2-D7AE-4D55-8E6A-C417A5B46C57 Q35742442-2C806929-B6E5-40F5-8C38-F84425FE7CD5 Q35864226-D4A3295A-DD9C-4B91-9E52-474DF3D7BD0E Q35894347-D1419349-6FD8-4612-B809-12B365995AD5 Q35895174-777C00FA-9984-4DD0-8A43-6F5C08369FBC Q36121570-814657CE-244F-4F2C-A1A4-4B67227DC86E Q36224048-9E110DCD-0345-4F04-9C6D-F4022B51F2A5 Q36280795-5CD34E97-768B-4B67-8110-5EDEAD41D903 Q36413606-B6FC1025-5B2A-4E2D-AD4E-4AF51D1266D6 Q36462348-EFCD0D89-4835-43CD-8BED-F8B8F52B0E57 Q36511945-AB00CD7A-E9C8-48EC-82FE-D89CBD08A82B Q36560310-C9759484-C02A-4342-B277-824CA1B728EE Q36636067-36F4E5E2-B6DD-429F-A83C-281BDC98BEB7

P2860

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

http://www.wikidata.org/entity/Q34480536

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeted therapy for high-grad ...... and controlled phase IIb study

@ast

Targeted therapy for high-grad ...... and controlled phase IIb study

@en

Targeted therapy for high-grad ...... and controlled phase IIb study

@nl

type

label

Targeted therapy for high-grad ...... and controlled phase IIb study

@ast

Targeted therapy for high-grad ...... and controlled phase IIb study

@en

Targeted therapy for high-grad ...... and controlled phase IIb study

@nl

prefLabel

Targeted therapy for high-grad ...... and controlled phase IIb study

@ast

Targeted therapy for high-grad ...... and controlled phase IIb study

@en

Targeted therapy for high-grad ...... and controlled phase IIb study

@nl

P1433

Q34480536-5B38708F-AEE5-431B-9CAD-8E0CBE62A2A0

P1476

Q34480536-F54E7722-9D16-48B8-B634-CD2A2CB5C033

P2093

Q34480536-01004049-68EB-46AB-8BC0-08649A209784

Q34480536-090DBE9E-2596-4632-A790-54484D654B75

Q34480536-0C798E20-FDCB-4FD7-8C0C-DC4ABD17DCC1

Q34480536-16C42A9A-60A6-4DDA-A43D-387FDBE62DB9

Q34480536-17250F0F-7BDE-4D58-A330-A77189E580D9

Q34480536-296CBC99-C034-48C8-9772-88219D38DE94

Q34480536-3E34ADCB-7731-4DDA-9562-8B0CF2982F78

Q34480536-4946C3CC-A909-4B9F-B815-BDA69080ED6D

Q34480536-4BDB6B50-6EA6-4422-B252-D711C61A8B82

Q34480536-6AAA7158-16B5-4B34-BC0E-94FFB0DCB3CB

P2860

Q34480536-180A66B6-CF13-4698-90C3-66CE442A3E2E

Q34480536-2CAA95E8-B062-4E97-BD74-3BA8C7CC3EE9

Q34480536-34318750-651E-496D-8641-853A24F9C716

Q34480536-3C14D4CA-B7A5-4FDB-A19B-F0BB6119F609

Q34480536-3E8C8FB4-D71A-4025-B1F7-D15155927464

Q34480536-3F0D2271-D181-4DC2-B31F-5F1EE0472EDF

Q34480536-496E5CB8-3EAF-4B92-A75D-EBE5AACE9DD5

Q34480536-4B51113C-D163-48F0-AEE4-66F7A9FB044A

Q34480536-5C4CA2E0-9C79-4139-8D05-F84300CDCA0B

Q34480536-6A1B9B6E-1105-4035-97AB-726EAC8849A8

P304

Q34480536-C3C27023-46A7-40BA-8319-C8B582F37D0B

P31

Q34480536-8595CA21-9EB7-46F1-B189-9AF6D3E44E9E

P356

Q34480536-3E95D175-CF2C-43DD-AA43-70A167F807AC

P433

Q34480536-49415E27-90FB-428B-A85A-1D61551623AA

P478

Q34480536-5053FFD8-3A1A-47B5-9E41-6B09ABD410A9

P50

Q34480536-35A6B838-FAC4-4FD5-851E-9A8AED48EC2B

P577

Q34480536-1CC11674-CED0-4908-976B-C883919FFA66

P5875

Q34480536-FABF841D-8A2B-4C1C-AE8A-4629982E3A1E

P698

Q34480536-357023E3-22C6-4849-B764-58258623DEC3

P932

Q34480536-18F27B3F-94AD-4E78-873B-4E21A275733B

P356

P1433

P1476

Targeted therapy for high-grad ...... and controlled phase IIb study

@en

P2093

A Balasubramaniam

http://www.w3.org/2001/XMLSchema#string

A K Mahapatra

http://www.w3.org/2001/XMLSchema#string

A Suri

http://www.w3.org/2001/XMLSchema#string

G Stockhammer

http://www.w3.org/2001/XMLSchema#string

H Heinrichs

http://www.w3.org/2001/XMLSchema#string

I Poverennova

http://www.w3.org/2001/XMLSchema#string

K-H Schlingensiepen

http://www.w3.org/2001/XMLSchema#string

M Zaaroor

http://www.w3.org/2001/XMLSchema#string

N K Venkataramana

http://www.w3.org/2001/XMLSchema#string

P Jachimczak

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

TGFbeta in Cancer

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Temozolomide in the treatment of recurrent malignant glioma.

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

A clinical development paradigm for cancer vaccines and related biologics.

Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis

P304

132-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ142

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47566329

http://www.w3.org/2001/XMLSchema#string

P698

20980335

http://www.w3.org/2001/XMLSchema#string

P932

3018908

http://www.w3.org/2001/XMLSchema#string